BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Ingenium Pharmaceuticals Signs INGENOtyping(TM) Agreement With Max-Planck-Institute for Immunobiology


10/19/2005 5:09:33 PM

MUNICH, Dec. 19 /PRNewswire/ -- Ingenium Pharmaceuticals AG announced today an INGENOtyping(TM) agreement with the Max-Planck Institute of Immunobiology, located in Freiburg, Germany. Ingenium will provide genetic mouse models for target genes to the Max-Planck Institute using its INGENOtyping(TM) platform. This agreement brings the total number of INGENOtyping(TM) partnerships signed in 2003 to 10.

Separately, Ingenium announced an agreement with the German National Research Center for Environment and Health GmbH (GSF) to access an additional murine tissue archive. The deal is the second in-licensing agreement with the GSF. This increase, combined with Ingenium's internal production, will create the world's largest sperm archive, encompassing over 10,000 individual samples, from which high value murine models can be produced. The average number of functional gene variants on a gene-by-gene basis for the entire archive is estimated to be five, allowing the rapid production between three to five different murine variants per gene of interest. The agreement with the GSF was negotiated with its commercialization arm, Ascenion. For both agreements, no financial or other terms were disclosed.

Ingenium also updated investors and current and prospective corporate partners on its success applying the INGENOtyping(TM) technology to the production of rat genetic models. Ingenium has confirmed four unique rat models with novel mutations generated in G-Protein Coupled Receptor (GPcR)- type drug targets, with more models in production.

"INGENOtyping(TM) provides a significant speed benefit in the actual process time for producing genetic mouse models, which is less than four weeks," stated Michael Nehls, M.D., Ph.D., Chief Executive at Ingenium. "The strength of the platform has been recognized through our partnerships with leading companies and world-class research institutes such as Max-Planck. We see future growth through the application of the technology to the production of genetic rat models, which will be a major technological advance for pharmaceutical development and drug compound testing. By providing the first industrial scale pipeline of genetically defined rat models, we are uniquely positioned to provide our partners with advantages in production speed and access to an unique resource."

Prof. Dr. Thomas Boehm, Executive Director of the Max-Planck Institute Freiburg stated, "I am impressed with the efficiency with which Ingenium was able to identify exciting genetic variants for our research programs. I am excited that such a professional platform is now accessible for academic research."

Dr. Nehls added: "The importance of genetic mouse models can not be disputed, however pharmaceutical development requires speed, which standard KO technology can not provide on the scale needed. For rats, alternative technologies are only in developmental stages."

Ingenium's INGENOtyping(TM) technology is a high-speed second-generation tool for the in vivo validation of drug targets. INGENOtyping(TM) can provide with as little as four weeks process time a series of mammalian models that carry unique genetic alterations in any target gene of interest. These models include knockouts as well as more subtle functional alterations, such as increased and reduced gene target activity. The INGENOtyping(TM) technology is based on a genetically subtle chemical process that generates point mutations in genes and Ingenium's expertise in quickly and reliably producing and analyzing mammalian models of disease.

The research institutes of the Max Planck Society perform basic research in the interest of the general public in the natural sciences, life sciences, social sciences, and the humanities. In particular, the Max Planck Society takes up new and innovative research areas that German universities are not in a position to accommodate or deal with adequately. These interdisciplinary research areas often do not fit into the university organization, or they require more funds for personnel and equipment than those available at universities. The variety of topics in the natural sciences and the humanities at Max Planck Institutes complement the work done at universities and other research facilities in important research fields. In certain areas, the institutes occupy key positions, while other institutes complement ongoing research. Moreover, some institutes perform service functions for research performed at universities by providing equipment and facilities to a wide range of scientists, such as telescopes, large-scale equipment, specialized libraries, and documentary resources.

The basis of Ingenium's business is its knowledge and expertise in generating the biological information critical to the discovery, validation and development of therapeutics. Ingenium's biology-based target discovery technology, Deductive Genomics(TM), involves a functional genomics analysis of an entire mammalian genome to locate novel therapeutic entry points to treat disease. From the breadth of knowledge generated by Deductive Genomics(TM), Ingenium is currently advancing a pipeline of novel models and biologically validated drug targets in the areas of inflammatory bowel disease, neurodegeneration and metabolic disorders. Ingenium has research partnership agreements with Elan Corporation, Bayer AG, F. Hoffmann-La Roche Ltd., Sequenom Inc., and Oxagen Ltd., in addition to numerous international academic collaborations.

For more information contact: Gretchen L.P. Schweitzer Vice President Corporate Communications Ingenium Pharmaceuticals AG Ph: 49 (89) 8565-2398 gretchen.schweitzer@ingenium-ag.com

Ingenium Pharmaceuticals AG

CONTACT: Gretchen L.P. Schweitzer, Vice President CorporateCommunications of Ingenium Pharmaceuticals AG, Ph: 49 (89) 8565-2398,gretchen.schweitzer@ingenium-ag.com


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->